‘Regulatory Sandbox’ In EU's Sights For Innovative Drug Development & Approval
Executive Summary
The European Commission’s vision for a more agile and streamlined drug development and assessment framework includes the use of controlled regulatory environments for testing innovative new drugs and technologies.
You may also be interested in...
Regulators Need New Skills & Smarter Guidance To Govern AI, Says EMA Chief
A two-day workshop saw EU policymakers and regulators meet with dozens of representatives from the pharmaceutical, health and medtech industries to discuss the future of regulating AI in medicine and its uses in the medicinal product lifecycle.
EU Rapporteur Slams Commission’s ‘Regulatory Sandbox’ & Antimicrobial ‘Voucher’ Proposals
Tiemo Wölken has proposed a public “European Medicines Facility” to elaborate R&D projects focusing on the development of priority antimicrobials and medicines for other unmet medical needs. He also disagrees with his fellow rapporteur’s support for an increase in the regulatory data protection period.
What Would An EU ‘Regulatory Sandbox’ Bring To New Drug Development?
Digital health, AI, real-world evidence and “proactive learning” are key components of the EU’s proposals for new ways of regulating novel medicines, but only time will tell which products might benefit from the flexibilities offered by the “regulatory sandbox.”